Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 2Completed 2Available 1Active not recruiting 1

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Sarcoma 2

Conditions

Osteosarcoma 2

Interventions

Cyclophosphamide 1495Cisplatin 1431Paclitaxel 1339Radiotherapy 1308Carboplatin 1264Gemcitabine 1225Docetaxel 1134Bevacizumab 1068Fluorouracil 906Doxorubicin 799Dexamethasone 753Rituximab 744Capecitabine 735Oxaliplatin 709pembrolizumab 693Etoposide 674Irinotecan 639Filgrastim 624Nivolumab 585Cytarabine 585Leucovorin 582Vincristine 512Cetuximab 478Prednisone 477Bortezomib 472Trastuzumab 469Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 443Lenalidomide 434

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × mifamurtide × Clear all
NCT01459484 2024-05-20

ISG/OS-2

Italian Sarcoma Group

Phase 2 Completed
225 enrolled
Sarcoma

Osteosarcoma

NCT00631631 2014-05-14

Mifamurtide (L-MTP-PE) for High-Risk Osteosarcoma

Millennium Pharmaceuticals, Inc.

Completed
205 enrolled
Sarcoma

Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡